User profiles for J A Thompson

John F Thompson

Melanoma Institute Australia
Verified email at melanoma.org.au
Cited by 83217

[HTML][HTML] Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

…, E Solska, G Wilding, JA Thompson… - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
Purpose A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa
(IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic …

[PDF][PDF] Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

…, A Sober, JA Thompson, JF Thompson - Journal of Clinical …, 2001 - jfisher.pbworks.com
Purpose: To revise the staging system for cutaneous melanoma under the auspices of the
American Joint Committee on Cancer (AJCC). Materials and Methods: The prognostic factors …

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

…, JM Kirkwood, MB Atkins, JA Thompson… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: The American Joint Committee on Cancer (AJCC) recently proposed major
revisions of the tumor-node-metastases (TNM) categories and stage groupings for cutaneous …

The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog.

WR Martin, CG Eades, JA Thompson… - … of Pharmacology and …, 1976 - ASPET
Three different syndromes produced by congeners of morphine have been identified in the
nondependent chronic spinal dog. These syndromes have been attributed to interaction of …

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

…, C Porta, S Bracarda, V Grünwald, JA Thompson… - The Lancet, 2008 - thelancet.com
Background Everolimus (RAD001) is an orally administered inhibitor of the mammalian
target of rapamycin (mTOR), a therapeutic target for metastatic renal cell carcinoma. We did a …

[HTML][HTML] Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical …

…, JS Weber, JD Wolchok, JA Thompson - Journal of clinical …, 2018 - ncbi.nlm.nih.gov
Purpose To increase awareness, outline strategies, and offer guidance on the recommended
management of immune-related adverse events in patients treated with immune …

Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update

…, U Swami, JA Thompson… - Journal of clinical …, 2021 - ingentaconnect.com
PURPOSE To increase awareness, outline strategies, and offer guidance on the recommended
management of immune-related adverse events (irAEs) in patients treated with immune …

Health literacy and mortality among elderly persons

…, JA Thompson, JA Gazmararian… - Archives of internal …, 2007 - jamanetwork.com
Background Individuals with low levels of health literacy have less health knowledge, worse
self-management of chronic disease, lower use of preventive services, and worse health in …

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor …

C Yee, JA Thompson, D Byrd… - Proceedings of the …, 2002 - National Acad Sciences
Adoptive T cell therapy, involving the ex vivo selection and expansion of antigen-specific T
cell clones, provides a means of augmenting antigen-specific immunity without the in vivo …

The call of the wild: Zookeepers, callings, and the double-edged sword of deeply meaningful work

JS Bunderson, JA Thompson - Administrative science …, 2009 - journals.sagepub.com
A qualitative examination of work meaning in the zoo-keeping profession pointed to the
centrality of the notion of work as a personal calling. The view of calling expressed by …